Tag Archives: Johnson & Johnson

Pharma Funding & Shrinks for Sale—The Creation of Pre-school Age Bipolar Epidemic

It is difficult to absorb the recent data released by the Agency for Healthcare Research and Quality, AHRQ, and not come to the conclusion that this startling information represents the never-ending harm initiated by the idiotic psychiatric theories of Harvard child psychiatrist, Dr. Joseph Biederman.

In order to fully grasp just how outrageous the data are, one first must remember that the now disgraced and marginalized Biederman is credited with being the ring leader for diagnosing the alleged bipolar disorder in very young children.

Risperdal causes teenage boy to grow ‘D cup’ breasts; Judge lets CEO of company off the hook regardless

Big Pharma firm Johnson & Johnson, maker of the antipsychotic drug Risperdal, owes hundreds of millions of dollars to several states over improper marketing of the medication and for encouraging doctors to prescribe it for non-approved uses, but because the case was settled in court the company’s CEO, Alex Gorsky, won’t have to testify about allegations his company’s drug caused some young boys to grow breasts, among others.

Risperdal causes teenage boy to grow ‘D cup’ breasts; Judge lets CEO of company off the hook regardless

The Huffington Post—Drug Companies Drive the Psychiatric Drugging of Children

Johnson & Johnson, the company that makes the antipsychotic drug Risperdal, has tentatively agreed to a settlement of $2.2 billion to resolve a federal investigation into the company’s marketing practices.

State of Texas prescribed anti-psychotic drug to youth offenders while challenging its effectiveness in court

Left hand, we’d like to introduce you to the right.

For two years while the state of Texas was suing Johnson & Johnson for fraudulently inflating the cost and effectiveness of the anti-psychotic drug Risperdal, taxpayers picked up a $247,666.87 bill for the Texas Youth Commission to continue prescribing the drug to young inmates.

Johnson & Johnson and a subsidiary, Janssen Pharmaceuticals Inc., agreed in January to pay the state $158 million to settle the lawsuit. The state had been seeking $579 million.